Retatrutide is an advanced next-generation metabolic peptide engineered as a triple agonist of the GLP-1, GIP, and glucagon receptors. By simultaneously targeting appetite regulation, insulin sensitivity, and energy expenditure, Retatrutide is widely studied for its exceptional effects on weight reduction, glucose control, and overall metabolic efficiency.
$160.00
For laboratory research use only. Not for human or animal use or consumption. Not a drug, food, dietary supplement, or cosmetic. Not approved by the FDA for any medical use.
Retatrutide is a novel synthetic peptide classified as a triple incretin and glucagon receptor agonist, uniquely designed to activate three key metabolic pathways:
GLP-1 receptor (GLP-1R)
Glucose-dependent insulinotropic polypeptide receptor (GIPR)
Glucagon receptor (GCGR)
This tri-receptor activity allows Retatrutide to deliver a broader and more potent metabolic response than traditional single- or dual-agonist peptides.
Through GLP-1 and GIP receptor activation, Retatrutide enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, delays gastric emptying, and significantly reduces appetite. Simultaneously, GCGR activation increases energy expenditure and fat oxidation, promoting a higher metabolic rate and enhanced weight-loss outcomes.
The combined effect is a powerful improvement in glycemic control, insulin sensitivity, and body composition, with research demonstrating substantial reductions in body weight, visceral fat, and cardiometabolic risk markers. Its extended duration of action supports once-weekly administration, allowing for sustained receptor engagement and consistent metabolic benefits.
Retatrutide represents a new frontier in metabolic research, offering insight into multi-pathway hormone signaling and its role in obesity, insulin resistance, and metabolic disease. Ongoing studies continue to explore its long-term potential across endocrine, cardiovascular, and energy-regulation systems.
Reviews
There are no reviews yet.